Precipio Announces Q2-2025 Shareholder Update Call
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q2-2025 shareholder update conference call for August 14th, 2025 at 5:00 PM ET. The call will provide updates on the company's core business segments.
Shareholders can access the call by dialing 800.717.1738. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call through Precipio's investor relations website.
Precipio (NASDAQ: PRPO), un'azienda specializzata in diagnostica oncologica, ha programmato la conference call di aggiornamento per gli azionisti relativa al secondo trimestre 2025 per il 14 agosto 2025 alle 17:00 ET. Durante la chiamata verranno forniti aggiornamenti sui principali segmenti di business dell'azienda.
Gli azionisti possono partecipare chiamando il numero 800.717.1738. Le domande possono essere inviate in anticipo via email all'indirizzo investors@precipiodx.com. Una registrazione della chiamata sarà disponibile circa 24 ore dopo, tramite il sito web delle relazioni con gli investitori di Precipio.
Precipio (NASDAQ: PRPO), una empresa especializada en diagnóstico oncológico, ha programado su llamada de actualización para accionistas del segundo trimestre de 2025 para el 14 de agosto de 2025 a las 5:00 PM ET. La llamada proporcionará actualizaciones sobre los principales segmentos del negocio de la compañía.
Los accionistas pueden acceder a la llamada marcando el 800.717.1738. Las preguntas pueden enviarse por adelantado por correo electrónico a investors@precipiodx.com. Una repetición estará disponible aproximadamente 24 horas después de la llamada a través del sitio web de relaciones con inversores de Precipio.
Precipio (NASDAQ: PRPO), 암 진단 전문 회사가 2025년 2분기 주주 업데이트 컨퍼런스 콜을 2025년 8월 14일 오후 5시 ET에 예정했습니다. 이번 콜에서는 회사의 핵심 사업 부문에 대한 최신 정보를 제공합니다.
주주들은 800.717.1738로 전화하여 콜에 참여할 수 있습니다. 질문은 사전에 investors@precipiodx.com으로 이메일로 제출할 수 있습니다. 콜 종료 약 24시간 후 Precipio 투자자 관계 웹사이트에서 다시 듣기가 제공됩니다.
Precipio (NASDAQ : PRPO), une société spécialisée dans le diagnostic du cancer, a programmé sa conférence téléphonique de mise à jour pour les actionnaires du deuxième trimestre 2025 le 14 août 2025 à 17h00 ET. L'appel fournira des mises à jour sur les segments clés de l'entreprise.
Les actionnaires peuvent accéder à l'appel en composant le 800.717.1738. Les questions peuvent être envoyées à l'avance par email à investors@precipiodx.com. Une rediffusion sera disponible environ 24 heures après l'appel via le site web des relations investisseurs de Precipio.
Precipio (NASDAQ: PRPO), ein auf Krebsdiagnostik spezialisiertes Unternehmen, hat seine Aktionärs-Update-Konferenzschaltung für das zweite Quartal 2025 für den 14. August 2025 um 17:00 Uhr ET angesetzt. Während des Anrufs werden Updates zu den Kern-Geschäftsbereichen des Unternehmens gegeben.
Aktionäre können die Telefonkonferenz unter der Nummer 800.717.1738 erreichen. Fragen können im Voraus per E-Mail an investors@precipiodx.com eingereicht werden. Eine Aufzeichnung wird etwa 24 Stunden nach dem Anruf über die Investor-Relations-Website von Precipio verfügbar sein.
- None.
- None.
Conference Call to be held on August 14th, 2025 at 5:00 PM EST
NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses.
The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call.
Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call.
A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio's website, https://www.precipiodx.com/investors/.
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523